Derkach Nemirovsky

13PUBLICATIONS
68CO-AUTHORS
Haematological tumoursPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical mycologyPharmacology and pharmaceutical sciences not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 21, 2026
Clinically Relevant Outcomes With Romiplostim in Patients With Solid Tumors and Persistent Chemotherapy Induced Thrombocytopenia.

|Jul 29, 2026
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.

|Apr 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve

|Oct 04, 2025
Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease.

Gagan Raju, Moneeza Walji, David Nemirovsky

|Aug 25, 2025
Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance.

Ross S Firestone, Anish K Simhal, Devin McAvoy

|Jan 08, 2024
Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.

Aaron P Mitchell, David Nemirovsky, Akriti Mishra Meza

Pageof 3

Frequent Collaborators

7 joint publications

Sridevi Rajeeve

7 joint publications

Sergio Giralt

7 joint publications

Gunjan Shah

7 joint publications

Heather Landau